Anacor Pharmaceuticals, Inc.

Warner-lambert Company

Synphar Laboratories, Inc.

Taiho Pharmaceutical Company Limited

National Research Council of Canada

Naeja Pharmaceutical Inc.

Other

Intervet Inc.

Schering-plough Animal Health Corporation

Pantherix, Ltd.

Naeja Pharmaceuticals Inc.

Synphar Laboraties, Inc.

Basilea Pharmaceutica Ag

Rajeshwar Singh

Ronald G Micetich

Jacob J Plattner

Yong-Kang Zhang

Tsutomu Akama

Stephen J Baker

Michael Richard Kevin Alley

Michael Andrew Stier

Kirk R Maples

Edmund Lee Ellsworth

James Nieman

Rashmi Sharma

John Michael Domagala

George Thomas

Stephen J Benkovic

Ving J Lee

Vincent S Hernandez

Joseph P Sanchez

Deqi Guo

Fernando Rock

Yi Xia

Dai Q Nguyen

Carolyn Bellinger-Kawahara

Howard Daniel Hollis Showalter

Hiroshi Matsumoto

Tomohiro Yamashita

Charles Z Ding

Ronald J Micetich

Charles Y Fiakpui

Zhuoyi Su

Scott J Hecker

Tomasz W Glinka

Virginia J Sanders

Robert Toms Jacobs

Brian Morgan Watson

Samarendra N Maiti

Mark Whittaker

Yvonne Freund

Daitao Chen

Tuan Phong Tran

Judy Yip

Peter Laurence Toogood

James S Kaltenbronn

Ding Zhou

Yasheen Zhou

Ellen Myra Dobrusin

James G Phillips

Nian E Zhou

Liren Huang

Vittorio A Sauro

Jadwiga Kaleta

Toshio Otani

Enrico O Purisima

Shinji Oie

Chan M Ha

Thomas Eric Renau

Dale Edward Shuster

Paul Bird

Nian Zhou

Maureen Elizabeth Carey

Albert Kudzoi Amegadzie

Arkadii Vaisburg

Xiaosong Lu

Marcelo Sales

Andhe V Narender Reddy

Inder Pal Singh

Mark Robert Barvian

Huchen Zhou

Roy Thomas Winters

Kathy Jingyuan Cao

Philip Huxley

Zhixiang Yang

Andhe V Reddy

Damayanthi Yalamati

Chieko Kunugita

Fusahiro Higashitani

Oludotun A Phillips

Guofeng Jia

Qizhu Ding

Eduardo Luis Setti

Chetan Pandit

Tatsuya Uji

Koichi Nishida

Rahim Mohammad

Dai Quoc Nguyen

Andhe V N Reddy

Praveen Baradi

Shouming Wang

Stephen Keith Wrigley

Michael Roe

David Michael Thornton

Ligong Ou

Neerja Saraswat

Sreekanth Ramachandran

Rakhshandeh Fathi-Afshar

Thomas R Doerksen

Maya P Singh

Mark Tempest

Inderjit S Sidhu

Yadagiri Bathini

Compounds of formula I that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase, pharmaceutical compositions including such compounds and methods of treating diseases, conditions or disorders utilizing such compounds and compositions. 

Substituted tetrahydropyridine derivatives as IDO-1 inhibitors and uses thereof

This invention provides, among other things, novel compounds useful for treating bacterial infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.

Boron-containing small molecules

The compounds are of the class of 3,7 substituted benzoxaboroles, useful for killing and/or inhibiting the growth of microorganisms.

Novel monosubstituted and disubstutituted oxaboroles and pharmaceutical compositions containing such oxaboroles are provided, which are useful for treating bacterial infections, as well as combinations of these oxaboroles with at least one additional therapeutically effective agent.

Boron containing small molecules

Compounds and methods of treating anti-inflammatory conditions are disclosed.

Boron-containing small molecules as anti-inflammatory agents

This invention largely relates to 3,4,6-trisubstituted benzoxaborole compounds, and their use for treating bacterial infections.

Trisubstituted boron-containing molecules

Compositions and methods of use of boron derivatives, including benzoxaboroles, benzazaboroles and benzthiaboroles, as therapeutic agents for treatment of diseases caused by fungi, yeast, bacteria or viruses are disclosed, as well as methods for synthesis of said agents and compositions thereof.

Hydrolytically-resistant boron-containing therapeutics and methods of use

Compositions and methods of use of borole derivatives, including benzoxaboroles, benzazaboroles and benzthiaboroles, as therapeutic agents for treatment of diseases caused by bacteria or viruses are disclosed, as well as methods for synthesis of said agents and compositions thereof.

This invention provides, among other things, novel oxaboroles which are monosubstituted at the 3-, 6-, or 7-position, or disubstituted at the 3-/6- or 3-/7- positions, which are useful for treating bacterial infections, pharmaceutical compositions containing such oxaboroles, as well as combinations of these oxaboroles with at least one additional therapeutically effective agent.

Novel florfenicol compounds having the chemical structure: 

Antibacterial 1-(4-mono-and di-halomethylsulphonylphenyl)-2-acylamino-3-fluoroproponals and preparation thereof

Antibacterial 3-aminoquinazolin-2,4-diones have formula (I) wherein: Rand Rinclude alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic, and heteroaryl; R, R, and Rinclude H, alkyl, alkoxy, halo, NO, CN, NH, alkyl and dialkylamino; Rincludes hydrogen, alkyl, cycloalkyl, heterocyclic, fused heterocyclic, aryl and fused aryl; J and K are C or N; and pharmaceutically acceptable salts thereof. 

3-aminoquinazolin-2,4-dione antibacterial agents

The structure and preparation of antibiotics incorporating borinic acid complexes are disclosed, especially hydroxyquinoline, imidazole and picolinic acid derivatives, along with compositions of these antibiotics and methods of using the antibiotics and compositions as bactericidal and fungicidal agents as well as therapeutic agents for the treatment of diseases caused by bacteria and fungi.

Antibiotics containing borinic acid complexes and methods of use

Antibacterial 1-(4-mono- and di-halomethylsulphonylphenyl)-2-acylamino-3-fluoroproponals and preparation thereof

Growing community of inventors

Edmonton, Canada

Rajeshwar Singh